HAVCR2 and non-small cell lung carcinoma: Moreover, bispecific antibodies (BsAbs) that can simultaneously block TIM-3 and PD-1 are also explored in ongoing trials involving NSCLC patients [NCT03708328 (182, 185); NCT04931654 (186)].